BRD8 Antibody

Rabbit Polyclonal

Antigen Affinity Purified Protein ID Q9H0E9
Catalog No. A300–220A GeneID 10902

Lot No. A300-220A-2

APPLICATIONS WB, IP, IHC
SPECIES REACTIVITY Human

PRESUMED REACTIVITY Based on 100% sequence identity, this antibody is predicted to react with Rat, Dog, Horse,

Rabbit, Guinea pig_10141, Pig, Panda, Monkey and Gorilla

AMOUNT 100 μl

CONCENTRATION 1000 μg/ml

STORAGE/SHELF LIFE 2 - 8° C / 1 year from date of receipt

PHYSICAL STATE Liquid

BUFFER Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide

ISOTYPE IgG
ORIGIN USA

PRODUCTION PROCEDURES

Antibody was affinity purified using an epitope specific to BRD8 immobilized on solid support.

The epitope recognized by A300–220A maps to a region found within isoform 2 between residues 225 and 275 of human Bromodomain containing 8 using the numbering given in Swiss-

Prot entry Q9H0E9.2 (GeneID 10902).

Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm

of 1.4 equals 1.0 mg of IgG.

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined

experimentally by the investigator. Prepare working dilution immediately before use.

Western Blot 1:2,000 - 1:10,000

Immunoprecipitation 2 – 8 µg/mg lysate

Immunohistochemistry 1:500 - 1:2,000. Epitope retrieval with citrate buffer pH 6.0 is

recommended for FFPE tissue sections.

APPLICATION NOTES Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. \$100-020),

Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120-113P) and 4-8% SDS-PAGE

(link to IP-western blot protocol in Additional Info section below).

Western blot of lysates performed using standard western blot reagents and 4-8% SDS-PAGE.

IHC HUMAN CONTROLS Breast Carcinoma, Prostate Carcinoma

ADDITIONAL INFO https://www.bethyl.com/product/A300-220A


Use the link above to view SDS, a current list of citations, and other product specific information.


IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc. Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019




BRD8 Antibody A300-220A





Detection of human BRD8 by western blot. Samples: Nuclear extract (50 μ g) from HeLa and HEK293T cells. Antibodies: Affinity purified rabbit anti-BRD8 antibody A300-220A (lot A300-220A-2) used for WB at 0.1 μ g/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.

Detection of human BRD8 by western blot of immunoprecipitates. Samples: Nuclear extract (0.5 or 1 mg per IP reaction; 20% of IP loaded) from HeLa cells. Antibodies: Affinity purified rabbit anti-BRD8 antibody A300-220A (lot A300-220A-2) used for IP at 6 μg per reaction. BRD8 was also immunoprecipitated by a previous lot of this antibody (lot A300-220A-1). For blotting immunoprecipitated BRD8, A300-220A-2 was used at 1 μg/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.



Detection of human BRD8 by immunohistochemistry. *Sample:* FFPE section of human breast carcinoma. *Antibody:* Affinity purified rabbit anti-BRD8 (Cat. No. A300-220A Lot2) used at a dilution of 1:1,000 (1µg/ml). *Detection:* DAB